Charles River
CRL
Performance
About Charles River
Charles River provides essential early-stage drug development and preclinical research services, specializing in animal models, toxicology, and translational biology to support biopharmaceutical discovery and development. With global laboratories and vivarium facilities, they offer expertise in in vivo pharmacology, pharmacokinetics, and bioanalysis to advance medicines from early discovery to candidate selection. The company operates internationally, serving pharmaceutical, biotechnology, and academic clients across multiple regions.
Recent News
Thermo Fisher, Charles River Workforce Cuts; WuXi Signs Contract with Vertex
Opinion: For AI to Have Impact, the Industry Must Align on Data
Here Are Tuesday's Biggest Analyst Calls: Apple, Tesla, Amazon, GM, Crocs, Viking, Alphabet, Ford & More
Wells Fargo Investment Institute Downgrades Energy Sector to 'Unfavorable' On Limited War Premium
Charles River CEO Jim Foster to Retire; Samsung Bio Buys a GSK Factory
Charles River Laboratories Acquires PathoQuest and K.F. (Cambodia)
IQVIA Signs Agreement to Acquire Drug Discovery Assets From Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities
Dietary Fructo-Oligosaccharides Dose-Dependently Modulate the Microbiome and Suppress Type 2 Lung Inflammation in a Murine Model of House Dust Mite-Induced Allergic Asthma